Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of upadacitinib plus topical corticosteroids in moderate to severe atopic dermatitis
NL-OMON55809Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (3 arms), sponsored by AbbVie Inc. Primary endpoints: vIGA-AD 0/1 response at Week 16 and EASI 75 at Week 16. Started Mar 2019; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON55809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55809.